GlucoTrack Reports Decline in Financial Performance and Cash Reserves for First Half of 2026

GlucoTrack, Inc. reported a significant decline in its financial performance for the six months ending June 30, 2026, compared to the same period in 2025. The company recorded a net loss of $8.1 million, a decrease from the $11.6 million loss reported in the prior year. Total operating expenses for the first half of 2026 were approximately $7.6 million, down from $8.3 million in the previous year, primarily due to reduced research and development costs associated with the development of its Continuous Blood Glucose Monitor (CBGM). Research and development expenses decreased to $4.1 million from $5.0 million, while general and administrative expenses increased slightly to $3.5 million from $3.3 million.

In terms of liquidity, GlucoTrack's cash and cash equivalents fell sharply to $1.1 million as of June 30, 2026, down from $7.4 million at the end of 2025. This decline was attributed to cash used in operating activities amounting to $7.7 million, which was partially offset by $1.4 million in net proceeds from financing activities. The company has accumulated a deficit of $160 million, raising concerns about its ability to continue as a going concern without additional financing.

Strategically, GlucoTrack has undergone significant organizational changes, including a merger with Lokahi Therapeutics, which was finalized on July 14, 2026. This merger is expected to enhance the company's capabilities in developing innovative therapies for diabetes management. Additionally, the company has engaged in various financing activities, including a Bridge Financing that raised approximately $4.5 million through the issuance of convertible promissory notes and warrants. This financing is intended to support ongoing product development and operational needs.

Operationally, GlucoTrack has made strides in its product development, particularly with the CBGM, which is designed for individuals with Type 1 and Type 2 diabetes. The company has completed several clinical studies and submitted an Investigational Device Exemption (IDE) application to the FDA, marking a critical step toward initiating U.S. clinical trials. However, the company has also faced challenges, including the closure of a long-term feasibility study in Australia due to product updates and protocol modifications.

Looking ahead, GlucoTrack's management has expressed optimism about securing additional financing to support its operations and product development. However, they acknowledge the uncertainty surrounding their ability to raise capital on favorable terms, which could impact their operational goals. The company plans to continue its efforts in clinical development and regulatory approval processes while addressing its liquidity challenges.